

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

NOD.Cg-Rag1^{tm1Mom} Il2rg/SzJ

RRID:IMSR_JAX:007799

Type: Organism

Proper Citation

RRID:IMSR_JAX:007799

Organism Information

URL: <https://www.jax.org/strain/007799>

Proper Citation: RRID:IMSR_JAX:007799

Description: Mus musculus with name NOD.Cg-Rag1^{tm1Mom} Il2rg/SzJ from IMSR.

Species: Mus musculus

Synonyms: NRG. NOD-RG. NOD-Rag1 IL2rg. NOD rag gamma

Notes: gene symbol note: recombination activating 1|interleukin 2 receptor; gamma chain|retinal degeneration 24; congenic strain: Rag1|Il2rg|rd24

Affected Gene: recombination activating 1|interleukin 2 receptor; gamma chain|retinal degeneration 24

Genomic Alteration: targeted mutation 1; Peter Mombaerts|targeted mutation 1; Warren J Leonard|retinal degeneration 24

Catalog Number: JAX:007799

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Rag1^{tm1Mom} Il2rg/SzJ

Record Creation Time: 20250513T053704+0000

Record Last Update: 20260905T044447+0000

Ratings and Alerts

No rating or validation information has been found for NOD.Cg-Rag1^{tm1Mom} Il2rg/SzJ.

No alerts have been found for NOD.Cg-Rag1^{tm1Mom} Il2rg/SzJ.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Wang J, et al. (2026) Rapid activation of ARF6 after RAF inhibition augments BRAFV600E and promotes therapy resistance. *Oncogene*, 45(23), 2286.

Norouzi M, et al. (2026) DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma. *Cancer letters*, 646, 218383.

Bidkar AP, et al. (2026) Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1540.

O'Toole KT, et al. (2026) Identification and characterization of BRAF^{WT}TP53 interactions in melanoma. *Cell reports*, 45(4), 117078.

Le BV, et al. (2026) Pol η activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia. *Cell reports. Medicine*, 7(3), 102687.

Bajgain P, et al. (2026) Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. *Cell reports. Medicine*, 7(5), 102782.

Wu L, et al. (2026) ICAM1^{high} Neutrophils Sculpt Tumor Evolution and Metastasis through Symbiotic Adhesion and Reverse Migration. *Cancer research*.

Park CK, et al. (2025) Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research. *JTO clinical and research reports*, 6(3), 100781.

Mukherjee S, et al. (2025) Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP inhibition. *Nature communications*, 16(1), 6999.

Portillo AL, et al. (2025) IL-21-reprogrammed V α 1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy. *Oncoimmunology*, 14(1), 2562210.

Olsen SN, et al. (2025) Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer. *Cell reports. Medicine*, 6(7), 102192.

Nishida-Aoki N, et al. (2025) Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. *Cell reports. Medicine*, 102357.

Zhang J, et al. (2025) An integrated proteomic portrait of prostate cancer progression. *Cell reports*, 44(6), 115828.

Young AA, et al. (2025) PACT suppresses PKR activation through dsRNA binding and dimerization, and is a therapeutic target for triple-negative breast cancer. *RNA (New York, N.Y.)*, 31(11), 1599.

Baral G, et al. (2025) PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma. *bioRxiv : the preprint server for biology*.

Greiner D, et al. (2025) Human CSPG4-targeting CAR-macrophages inhibit melanoma growth. *Oncogene*, 44(22), 1665.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. *Cancer cell*, 43(3), 428.

Kuzuoglu-Ozturk D, et al. (2025) Small-molecule RNA therapeutics to target prostate cancer. *Cancer cell*, 43(5), 841.

Richman CM, et al. (2025) Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy. *Cancer research*, 85(19), 3737.

Monavarian M, et al. (2025) ACTL6A regulates the Warburg effect through coordinated activation of AP-1 signaling in head and neck squamous cell carcinoma. *bioRxiv : the preprint server for biology*.